Statements (15)
Predicate | Object |
---|---|
gptkbp:instanceOf |
gptkb:chemical_compound
|
gptkbp:canBe |
osteoarthritis
pain management peripheral neuropathy |
gptkbp:CASNumber |
gptkb:641571-10-0
|
gptkbp:clinicalTrialPhase |
Phase II
|
gptkbp:developedBy |
gptkb:Pfizer
|
gptkbp:drugClass |
FAAH inhibitor
|
gptkbp:hasMolecularFormula |
C23H20F3N3O2
|
https://www.w3.org/2000/01/rdf-schema#label |
641571-10-0
|
gptkbp:IUPACName |
4-[2-(3-cyanopyridin-2-yl)-1H-indol-5-yl]-N-(2,2,2-trifluoroethyl)piperazine-1-carboxamide
|
gptkbp:molecularWeight |
427.42 g/mol
|
gptkbp:synonym |
gptkb:PF-04457845
|
gptkbp:bfsParent |
gptkb:Tasigna
|
gptkbp:bfsLayer |
5
|